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Abstract 
In 2007-2008, ARCADIS has conducted a study on behalf of the Flemish government, with as main 
objectives a review and a critical analysis of the existing calculations of environmental health costs 
in Flanders. This study covers the effects on human health of air pollution due to particulates and 
tropospheric ozone. Despite the large uncertainty surrounding individual estimates, we can be 
confident about the order of magnitude of the yearly marginal “cost of illness” due to PM2.5, PM10 
and ozone (a few dozens of millions EUR per 10µg/m³). If we also take into account the “subjective” 
health costs, our estimates run in the billion EUR. 
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1 Scope of the study 
In 2007-2008, ARCADIS has conducted a study on behalf of the Flemish government, with as main 
objectives a review and a critical analysis of the existing calculations of environmental health costs 
in Flanders.  
This study covers the effects on human health of air pollution due to particulates (PM2.5 and PM10) 
and tropospheric ozone5.  
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4 Metroeconomica. 
The approach for the quantification of the costs of the environmental effects follows the approach 
chosen in the ExternE projects6. ExternE follows the Impact Pathway Approach, which consists of 
the following steps: 
• Emissions inventory; 
• Dispersion modelling; 
• Exposure to concentration; 
• Quantification of physical impacts (based upon the concentration-response functions (CRF)); 
• Monetary valuation of these physical impacts. 
As existing approaches in Flanders use ambient concentrations, it is not relevant to undertake a 
critical analysis of emissions and dispersion modelling (step 1 and 2 in the impact pathway). These 
steps have therefore not further been considered in this work.  
This paper is structured as follows.  
In Section 2, we explain how the relationship between exposure to certain pollutants and certain 
health effects is described at the hand of impact functions. We also give a concise overview of the 
statistical methods used to estimate these functions.  
In Section 3, we give an overview of the methods used to value health effects. We explain why an 
economic analysis of health outcomes should not limit itself to estimates of the cost-of-illness (the 
out-of-pocket expenses due to illness on the one hand and the lost productivity on the other hand), 
but should also consider the willingness-to-pay (WTP) to avoid the pain and suffering caused by 
illness and premature death. Estimating this WTP requires the use of non-market valuation 
techniques.  
For the purposes of this study, we have limited ourselves to those health effects for which ExternE 
has published a so-called concentration-response function (CRF) linking ambient concentrations 
and health end-points.  Section 4 reviews these CRFs. 
Based upon these CRF, it is possible to make an inventory of the data that are needed to apply 
these CRFs to a Flemish context. Section 5 provides an overview of the data we have used for this 
purpose.  
In Section 6, we apply the data identified in Section 5 to the CRF reported in Section 4, and obtain 
an estimate of the health costs in Flanders that can be attributed to PM2.5, PM10 and ozone. We 
consider both the cost-of-illness and the “subjective” cost of the pain and suffering. 
In Section 7, we conclude and formulate policy recommendations. We especially emphasize the 
needs for further research. 
 
As this paper is based upon a report that exceeds the 200 pages, it is clearly not possible to 
provide a detailed description of all steps that were undertaken during the project. The emphasis 
lies on definitions, methodology and policy conclusions.     
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2 Impact functions 
Impact functions are necessary in step 4 of the impact pathway: they describe the relationship 
between exposure to pollutants and certain health effects.  
The quantification of health effects is usually expressed as the linking of two components (Hurley et 
al. (2005), p. 28): 
• A concentration-response (C-R) function, typically giving the rate of change in health 
endpoint, per unit change in pollutant ; 
• Background rates (incidence, prevalence) of health effect in the target population, where: 
Incidence refers to the number of new cases developing a specified condition, within a given 
population and time period; 
The prevalence of a disease is the total number of cases of the disease in the population at a 
given time. 
Linking these together, one can derive an impact function, as the number of attributable cases, 
per year, per unit population (e.g. per 100,000 people at risk), per unit exposure (e.g. per 10µg/m3). 
As explained in ExternE (2005, section 6.2), the dose-response function (DRF) relates the 
quantity of a pollutant that affects a receptor (e.g. population) to the physical impact on this receptor 
(e.g. incremental number of hospitalisations). In the case of classical air pollutants (NOx, SO2, O3, 
and particulates), the term dose-response function is formulated directly in terms of the 
concentration of a pollutant in the ambient air, accounting implicitly for the absorption of the 
pollutant from the air into the body. Often, the terms exposure-response function (ERF) or 
concentration-response function (CRF) are used. 
The CRFs for health impacts are often derived from epidemiological studies or from laboratory 
experiments with animals.  
As explained in Hurley et al. (2005, p. 19) one must distinguish between studies measuring acute 
effects and studies measuring chronic effects:  
• Most studies examine the effects of acute exposure; i.e. the ways that air pollution on a given 
day or adjacent days affects the health of people on the same day or on the days immediately 
following; 
• Other studies examine the relationships between health and long-term (i.e. chronic, possibly 
lifetime) exposure, and so the associated impacts are often known summarily as “chronic 
effects”. The effects of long-term exposure encapsulate the effects of daily variations in air 
pollution that comprise acute exposure, but they also include aspects which are not captured by 
(i.e. are more than the aggregate of) the effects of daily variations. 
The health effects associated with acute exposure to air pollution are often known as “acute health 
effects”, even though, strictly speaking, it is the exposure, not the effects, that is acute. For the sake 
of brevity, we shall, in what follows, refer to “acute” and “chronic” effects. 
In the ExternE methodology, it is assumed that the DRF for health impacts are linear, without 
threshold at the population level (even though thresholds can exist at the level of individuals or 
within homogeneous populations).  This assumption makes it possible to characterise a CRF with 
its slope only.  
Two types of regressions techniques are usually used to derive CRF. We will briefly discuss the 
analytical background and give a concrete example of a health point that is used in this study.  
2.1 Poisson regression 
As explained in Hurley et al. (2005, p. 28), Poisson regression is used for time series studies: 
• where the outcome variable is the daily number of events, 
• where the underlying population being studied is very large, and  
• where the probability of an adverse event in any one individual is very small. 
Typical examples are deaths and hospital admissions.  
It is then assumed that the health impact Y follows a Poisson distribution, whose expected value is 
predicted by an explanatory variable X. This health effect is usually measured on a logarithmic 
scale.  
Formally:  
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For discrete values, we obtain: ( ) ( ) ( )XYEbYE ∆=∆ ..  and thus (for 1)( =∆ x ): 
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1 + b is defined as the relative risk (RR). 
The impact function can then be calculated if one has data with respect to the background 
incidence E(Y) of the health effect under consideration. 
As an example, let us take the morbidity effects attributed to PM2.5 in ExternE. We consider three 
possible end points: restricted activity days (RAD), work loss days (WLD) and minor restricted 
activity days (MRAD).  
The explanatory variable is the average value of the last two weeks.  
We report the estimates value of the slop of the CRF, but also the lower bound (LB) and the upper 
bound (UB) of the 95% confidence interval.  
Table 1 CRF for ill health days attributable to 10 µg/m3 PM2.5 
Effect Population slope LB slope UB slope 
RAD  Adults 15-64 jaar  0.0475 0.0417 5.33 
WLD  Adults 15-64 jaar 0.046 0.039 0.053 
MRAD Adults 18-64 jaar 0.074 0.06 0.088 
Thus, an increase of the PM2.5 concentration with 10 µg/m3 per year leads to (within the relevant 
age category) an increase 
• Of the number of RAD with 4.75%. 
• Of the number of WLD with 4.6% 
• Of the number of MRAD with 7.4% 
We have then combined estimates of absenteeism in Flanders (see Section 5.4) with the above 
CRF to obtain a Flemish gender and age specific impact function for WLD – see Table 2. Similar 
results have been obtained for the other end points.  
Table 2 Flemish impact functions for absenteeism (in days) attributable to PM2.5  
Population slope LB slope UB slope 
Men (15 to 24) 33 220 28 165 38 276 
Men (25 to 49) 245 992 208 558 283 425 
Men  (50+) 69 728 59 117 80 339 
Women (15 to 24) 26 369 22 356 30 382 
Women (25 to 49) 217 720 184 589 250 851 
Women (50+) 39 582 33 559 45 605 
Total 632 611 536 344 728 878 
 
2.2 Logistic regression 
As explained in Hurley et al. (2005, p. 28), logistic regression is used when the outcome variable is 
binary, and the probability p of occurrence is approximated by the long run relative frequency of 
occurrences in the long run - this can arise in studying chronic disease (e.g. chronic bronchitis) or in 
panel studies of respiratory symptoms or medication usage. 
The dependent variable is then the logarithm of the “odds” (where the odds are defined as the ratio 
between the probability p that an effect occurs and the probability 1-p that it does not occur: 
p
p
o
−
=
1
).  
Formally:  
( ) Xo βα +=ln  
The coefficients of the logistic regression give the percentage change in the odds when the value of 
the pollutant changes:  
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The increase in the number of days per year where a given effect (per person in the relevant 
population) is observed is then: ( )( )( ))(.365 xpxxp −∆+ .  
The derivation of the impact function requires knowledge of the background odds.  
If p is very small, then po ≈ . It is then possible to interpret relative “odds” as if they were relative 
probabilities:  
( ) β≈=
dX
dp
pdX
pd 1ln
. 
For discrete changes, this gives: xpp ∆≈∆ .β , or (with 1)( =∆ x ): ( ) ( )xpxxp )1( β+≈∆+ . 
The increase in the number of days per year during which one measures a given effect (per person 
in the relevant population) is then: ( )( )( ) ( )xpxpxxp .365)(.365 β≈−∆+ .  
As an example, we consider the impact of PM10 on bronchodilator use by people who already 
suffer from asthma. Incidence is measured as the probability that an individual uses a 
bronchodilator on a given day (Hurley et al. (2005), p.95). 
Table 3: CRF for bronchodilator use attributable to PM10 
Effect Population Percentage total 
population 
Odds 
ratio 
Odds ratio 
LB 
Odds ratio 
UB 
Change in the number of days with 
bronchodilator use 
Children 5-14 
year  
25 1.005 0.981 1.029 
Change in the number of days with 
bronchodilator use 
Adults > 20 
years 
4.5 1.01 0.99 1.031 
In the original study, the probability of the event was 10% and the “background odds” was 0.11. The 
“small probability approximation” described above is then acceptable. An increase of the PM10 
concentration with 10 µg/m3 leads to an increase of the probability of bronchodilator use by an 
asthmatic child (adult) with 0.5% (1%) per day.  
To give another example, the table below gives the effect of PM10 on lower respiratory diseases. 
Incidence is measured as the number of symptom days per year. 
Table 4 for lower respiratory diseases attributable to PM10 
Effect Population odds 
ratio 
LB odds 
ratio 
UB odds 
ratio 
Increase in the number of 
symptom days per adult 
Adults with chronic respiratory problems (30% 
of the adult population) 
1 .017 1 .002 1 .032 
Increase in the number of 
symptom days per child 
Children 5-14 years 1 .04 1 .02 1 .06 
 
In the original study, the background incidence was 30% (15%) and the corresponding “background 
odds” were 0.43 (0.18) for children and adults, respectively. 
An increase of the concentration of PM10 with 10 µg/m3 per year leads to an increase in the odds 
of a symptom day with 1.7% (4%) respectively– this corresponds to odds of 0.373 for children and 
0.872 for adults. The probability of symtoms occurring are then 30.43% (15.79%) for children and 
adults respectively. 
 
2.3 Proportional hazard modelling 
Some CRF we have used are based upon “proportional hazard modelling”.  
Proportional hazards models are a sub-class of “survival models” in statistics. Survival models 
consist of two parts: the underlying hazard function, describing how hazard (risk) changes over time 
at baseline levels of covariates; and the effect parameters, describing how the hazard varies in 
response to explanatory covariates. The proportional hazards assumption is the assumption that 
covariates multiply hazard. For instance, if exposure to a pollutant doubles the risk at time 0, the 
risk also doubles at time t, for any t.   
These models can be approximated with Poisson models7.  
The following CRF for chronic mortality due to PM2.5 has estimated using “proportional hazard 
modelling”. 
Table 5. CRF for chronic mortality due to PM2.5 
Pollutant Effect RR LB 95% BI UB 95% BI 
PM2.5 “mortality hazard” per 10 µg/m3 1.05 NA NA 
This CRF has been calculated for a one-year long, not-recurring reduction in exposure. It is 
assumed that this reduction affects mortality risks during 10 years (Hurley et al., p 37).  
Hurley et al. have shown that this CRF implies that a reduction of PM2.5 concentrations by 10 
µg/m3 during one year leads to an increase in life expectancy of 651 years per 100.000 persons.  
3 Economic valuation of health effects 
Different perspectives can be taken when calculating the costs of illness and premature mortality. 
As usual in economic analysis, we will take the perspective of society in its totality.   
As argued in Choi and Pak (2002), this perspective has several characteristics.  
• Costs incurred by all sectors of society are included: individuals, employers, governments, the 
health care system, private health insurers, or shared arrangements between any of these 
sectors. 
• These costs also include the loss of forgone productivity (i.e., earnings) due to illness and injury 
or premature death but also a value associated with the forfeiture of an individual's healthy time. 
• The costs do not include transfer payments between parties within the society, such as social 
welfare payments, because these transfer payments only shift the burden from the individual to 
society and do not change the society's total resources. 
• Costs of administering transfer payments attributable to illness are included, because these 
administrative costs would not have been consumed in the absence of illness. 
As explained in Tarricone (2006), the economic costs of illness can be classified in three 
categories: 
• Direct costs refer to healthcare and non healthcare costs. The first have been defined as the 
medical care expenditures for diagnosis, treatment, continuing care, rehabilitation, and terminal 
care, while the second relate to the consumption of non healthcare resources, such as 
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transportation to and from health providers, certain household expenditures, costs of relocating 
and certain property losses, legal and court costs, and informal care, that is the time family 
members or volunteers spend caring for the patient.  
• Indirect costs refer to productivity losses related to illness or death.  
• Intangible costs refer to patients’ psychological pain and discomfort. 
Direct and indirect costs can, at least in principle, be estimated using accounting data.  
In order to estimate intangible costs, non-market valuation techniques need to be used. The 
following methods are usually used to estimate these cost: 
• Revealed preference methods: 
Hedonic pricing: The basic premise of the hedonic pricing method is that the price of a marketed 
good is related to its characteristics (including the environmental quality of its surroundings), 
or the services it provides. The “property value method” assumes that the price of a house is 
affected by the quality of the local environment, while the “compensating wage” method 
assumes that differences in risks between different occupations will be reflected in 
differences in wages. The “compensating wage” method is often used to estimate the value 
of a statistical life.  
The avertive behaviour approach examines the actual voluntary expenditures made by 
households on items (such as air conditioning) that reduce the impact of environmental end 
points, or examines the costs associated with any avertive behaviour aimed at reducing 
risks; 
• Stated preference methods: these methods directly elicit individuals’ Willingness to Pay for a 
change in an environmental end point (Contingent Valuation (CV)). 
The advantages and drawbacks of these methods have been discussed at length in the literature 
(see for instance Freeman (2003)) – our full report contains an extensive review of recent CV 
studies. 
In order to circumvent the problems with non-market valuation, the so-called cost of illness 
approach (COI) limits itself to an estimation of the direct and indirect cost of illness. The cost of 
illness is sometimes reported as giving a “lower bound” to the total welfare cost of illness, because 
it does not incorporate the suffering linked to illness and premature death. However, the actual 
relationship between the COI and the total welfare cost is more complex: 
• The COI depend on the organisation of the health care systems within individual countries 
(including a possible irrational allocation of resources); 
• Early deaths lead to a loss in productive activities, but also to a reduction in health care costs; 
• The COI has no welfare-economic meaning, as it reduces the value of people to their productive 
activities and are independent of the value they attach to their own life. 
Other issues are: 
• The absence of readily available data on medical costs for a particular type of illness (although 
databases, such as those available from the WHO, may help to address this problem); 
• The estimation of resource costs associated with fatal illnesses, in particular establishing the 
boundaries between fatal and non-fatal cases in terms of hospital treatment costs; 
• The problems associated with predicting how many currently non-fatal cases may result in 
deaths in the future (in order to avoid double-counting). 
Another specific issue in the valuation of health effects is the approach to take when valuating the 
cost of premature death. Basically two approaches are possible: 
• Value of statistical life. This can best be explained at the hand of an example. Take a group of 
10,000 people, each of whom has a probability of 0.0004 of dying next year. Suppose that a 
pollution control policy would reduce that probability to 0.0003, a change of 1 in 10,000. If each 
individual in the group is willing to pay 800 EUR for this policy, the total willingness to pay of the 
group is 8 million EUR. If the policy is adopted, on average, one person less will die per year. 
The value of a statistical life (VSL) in this group is then 8 million EUR.  
• Alternatively, one can use the Value of a Life Year Lost (VOLY). The main advantage of the 
VOLY concept is that the VSL does not take into account how many expected life years are lost 
whenever a premature death occurs.  
The preferred paradigm of deriving WTP values for health risk reductions from the willingness of 
individuals to pay for risk reductions that affect themselves clearly present difficulties in the case of 
children, as children have neither the maturity nor the financial resources to clearly define their 
willingness-to-pay. Therefore, an alternative perspective has to be adopted from which to estimate 
child health values.   
There are three potential perspectives from which preferences for children’s health risks might be 
elicited:  
• that of society (parents and non-parents),  
• that of adults placing themselves in the position of children, and  
• that of parents assessing risks faced by their own children  
There is a series of methodological issues that make transfer of values from adults to children 
difficult – we refer to the complete report for more details. 
A number of studies have examined possible differences of values between adults and children, but 
their findings have been mixed. In the context of this paper, the most important finding is that 
parents are more willing to pay to reduce their children’s health risks than their own. The estimated 
marginal rate of substitution (MRS) is generally greater than one, and is, on average close to 2. 
4 Concentration- response functions 
For the purposes of this study, we have limited ourselves to those health effects for which ExternE 
has published a CRF. In the case of particulates, we have considered the effect on premature 
deaths (both due to chronic and to acute exposure), on new cases of chronic bronchitis, on hospital 
admissions because of respiratory or heart problems, on consultations with primary care physicians 
for asthma or respiratory problems, on absenteeism and (in more general terms) the activity levels, 
on the use of bronchodilators and on the number of symptom days. In the case of ozone, we 
consider premature deaths (due to acute exposure), hospital admissions because of respiratory 
problems, consultations with primary care physicians for allergic rhinitis, reduced activity levels, 
bronchodilator use and symptom days. 
Several of these health end points are described in the “International Classification of Diseases” 
(ICD)8. The following table gives the correspondence between the “verbal” description of a health 
endpoint and the ICD: 
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Health end point ICD 
Respiratory problems 460-519 
Heart problems 390-429 
Allergic rhinitis 477 
Upper respiratory problems  
(with the exception of allergic rhinitis) 460-3; 465; 470-5 en 478  
Lower respiratory problems 
464, 466, 476, 480-3, 485-7,  
490-2, 494-6, 500, 501, 503-5,  
510-5, 518, 519, 786 
We list here the CRF we have used, with some clarifications where needed.  
4.1 Mortality  
The only CRF covering mortality due to chronic exposure has already been discussed in Section 
2.3. From this CRF, it follows that if PM2.5 concentrations decrease with 10 µg/m3 during one year, 
this leads to an expected gain of 651 year per 100 000 people. 
With respect to mortality due to acute exposure, three CRFs are used:  
Table 6. CRF for acute mortality due to PM10 and ozone 
Effect Slope LB slope UB slope 
% change in mortality in the adult population  
per 10 µg PM10/m3  
0.006 NA NA 
% change in mortality in the adult population  
per 10 µg ozone/m3 
0.003 0.001 0.0043 
% change in infant mortality per 10  µg PM10/m3 0.04 0.02 0.07 
ExternE assumes that 6 months of life are lost per premature death.  
4.2 Morbidity linked to PM10 
The following effects have been considered: 
• New cases of chronic bronchitis 
• Hospital admissions for respiratory or heart problems 
• Primary care consultations for asthma and upper respiratory problems (with the exceptions of 
allergic rhinitis). 
The exact CRFs are reported in the tables below. 
Table 7. CRF for new cases of chronic bronchitis 
Population Slope LB slope UB slope 
Adults > 27 years  0 .07 -0 .005 0 .143 
Note the slope of this CRF is not statistically significant. Moreover, these results are based upon 
one single study in a population with very specific behavioural patterns (7th Day Adventists in 
California). 
Table 8 CRF for hospital admissions attributed to PM10. 
ICD Slope LB slope UB slope 
460-519 0 .0114 0 .0062 0 .0167 
390-429 0 .006 0 .003 0 .009 
Table 9 CRF for primary care consultations attributed to PM10 
Health end point Population 
(age) 
Slope LB slope UB slope 
Astma 0-14  0 .025 0 .000 0 .052 
Astma 15-64  0 .031 0 .012 0 .050 
Astma 65+  0 .063 0 .021 0 .112 
ICD 460-3; 465; 470-5 en 478  0-14 0 .007 -0 .001 0 .014 
ICD 460-3; 465; 470-5 en 478  15-64  0 .018 0 .009 0 .028 
ICD 460-3; 465; 470-5 en 478  65+  0 .033 0 .017 0 .050 
 
Note that the CRF for upper respiratory problems is not significant for the age category 0-14.  
The CRF for bronchodilator use and for lower respiratory problems attributed to PM10 have already 
been discussed in Section 2.2.  
4.3 Morbidity linked to PM2.5 
The CRF for health end points attributed to PM2.5 have already been discussed in Section 2.2.  
4.4 Morbidity linked to ozone 
The following effects have been considered: 
• hospital admissions due to respiratory problems amongst people aged 65+ 
• minor restricted activity days (MRAD) 
• number of cough days (for children) 
• number of days with lower respiratory problems (except cough) (for children) 
• primary care consultations for allergic rhinitis 
• bronchodilator use by children with asthma 
• bronchodilator use by adults with asthma 
The exact CRFs are reported in the tables below. 
Table 10. CRF for hospital admissions due to respiratory problems amongst people aged 65+ 
attributed to ozone. 
Population slope LW slope UB slope 
Adults aged 65+ 0 .005 -0 .002 0 .012 
Note that this effect is not statistically significant.  
Table 11. CRF for MRAD attributed to ozone  
Population 
slope LW slope UB slope 
Adults 18-64 years 0 .0148 0 .0057 0 .0238 
The following CRF have been calculated for children aged 5-14 year from the general population.  
Table 12 CRF for symptom days amongst children attributed to ozone. 
Effect
9
 Odds 
ratio 
OG odds 
ratio 
BG odds 
ratio 
Change in the number of cough days 1 .05 0 .99 1 .12 
Change in the number of days with lower respiratory problems (except 
cough)  
1 .03 0 .92 1 .15 
The incidence rates were 5.4 % and 1 .5%, respectively. This implies that the background 
probability is a good approximation of the “background odds” (see section 2.2).   
Thus, an increase in ozone concentration with 10 µg/m3 per year leads to (in the population 5-14 
years): 
• An increase in the number of cough days with 5% 
• An increase in the number of days with lower respiratory problems (except cough) with 3% 
In the next CRF, the independent variable is the average concentration of the 4 past days. Because 
these results are based uniquely on studies in London, it is unclear to what extent the results can 
be extrapolated to Europe. 
Table 13 CRF for primary care consultations for allergic rhinitis attributed to ozone. 
Population Slope LB slope UB slope 
Children 0-14  0.082 0 .051 0 .116 
Adults 15-64  0 .055 0 .042 0 .07 
The next CRF and incidences have been estimated for children with asthma during “risk days”.  
Table 14 CRF for bronchodilator use by children with asthma (attributed to ozone). 
Effect Population Odds 
ratio 
LB odds 
ratio 
UB odds 
ratio 
Change in the probability of bronchodilator use 
during a risk day  
Children 5-14 year with 
asthma 
1 .41 1 .05 1 .89 
In the original study, the background probability of bronchodilator use during a “risk day” was 40% – 
this corresponds to a “background odds” of 0.66 (see Section 2.2). Thus, an increase in the ozone 
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concentration with 10 µg/m3 per year leads to an increase in the odds of bronchodilator use by an 
asthmatic child with 41% per risk day. If we use the “background odds” of the original study, we 
obtain that the odds increase to 0.94, which corresponds to a probability of 48.5%. Thus, the 
probability of bronchodilator use increases with 21%.  
It is not clear to what extent this result is representative. The original study was limited to a single 
location. The relation between bronchodilator use and ozone was only established for days where 
the children did not use corticosteroids. The observation period was limited from the beginning of 
April to the end of June. Finally, the calculation of the impact function in ExternE is based upon very 
specific assumptions – we refer to the full report for more details.  
The next CRF is based upon a sample of 75 adults older than 20 with asthma or COPD.  
Table 15. Impact of ozone on bronchodilator use by adults 
odds ratio 
OG odds 
ratio 
BG odds 
ratio 
Measured 
incidence in 
the summer 
Background 
odds in de 
zomer 
1 .009 0 .997 1 .02 0 .32 0 .47058824 
In the original study, a background incidence of 32% was observed, which corresponds to 
“background odds” of 0.4706 (see Section 2.2). 
Following the same calculations as above, it can be shown that an increase in ozone 
concentrations with 10 µg/m3 per year leads to an increase in the probability of bronchodilator use 
with 0.6%.  This relationship is not statistically significant.  
5 Data used 
5.1.1 Data needs for an application to Flanders 
For each of the effects described in Section 4, we have sought data on: 
• Incidence or prevalence rates (which are required to construct region-, gender- and age-specific 
impact functions); 
• The cost-of-illness: treatment costs on the one hand, lost productivity on the other hand; 
• The willingness-to-pay to reduce the pain and suffering related to illness and premature deaths.   
5.2 Data on incidence and prevalence rates  
For each health end point covered in this study, we need three types of data: 
• Data on hospital admissions due to this end point; 
• Data on the number of primary care consultations due to this end point; 
• Data on medication use due to this end point. 
We first verify the availability of date on hospital admissions.  
Data on emergency hospital admissions due to heart and respiratory problems have been obtained 
from the RCM-MKG10 database. This database registers the clinical data related to all admissions 
in non-psychiatric hospitals in Belgium.  
Table 16: Yearly number of emergency hospital admissions per 100 000 individuals in the Flemish 
Region 
Year 2001 2002 2003 2004 2005 
Respiratory problems 860 879 855 747 892 
Heart problems 759 746 733 721 738 
The figures for hospital admissions due to respiratory problems are significantly higher than the 
figures used in CAFE11: 617 per 100 000 for all ages (Hurley et al. pp 78-79), while the figures for 
heart problems are quite close to the figures used  in CAFE: 723 per 100 000 (Hurley et al. p 78-
79).  
The most important limitations of these data are: 
• It is possible to disaggregate these data up to the level of the “arrondissement” (in Belgium, this 
is the level of government grouping several municipalities). However, because individuals are 
not always admitted in hospitals within the “arrondissement” where they live, we have not 
sought a geographical differentiation of the date below the level of the Flemish Region.  
• Some people living in Flanders are admitted in hospitals in Wallonia or in Brussels (and vice 
versa). It is not possible to correct the data for this.  
• It is not clear to what extent the definition of “emergency hospital admissions due to heart and 
respiratory problems” used in the RCM-MKG database corresponds to the effects that were 
measured in the epidemiological studies that have lead to the estimates of the CRFs we have 
used here. 
• The RCM-MKG only registers the primary reason for the hospital admissions. Secondary 
diagnoses are not reported. 
However, the RCM-MKG data are still the best data that are currently available for the purposes of 
this project.  
Data on all other medical end points studied here are extremely scarce. For instance: 
• The reasons for consulting with primary care physicians are not routinely reported. 
• There are no centralised data on the sales of non-prescription drugs.  
• There are no structural data on the prevalence of asthma and chronic bronchitis in Belgium. 
Hence, we had to rely on indirect estimates.  
Our mean source of information has been the Intermutualistisch Agentschap (IMA)12.  The 
databank of IMA covers all Belgian residents. We have proceeded as follows: 
                                                          
10 Résumé Clinique Minimum- Minimale Klinische Gegevens.  
11 CAFÉ stands for Clean Air for Europe, the European Union’s thematic strategy for air quality.  
12 In Belgium, health insurance is mandatory. All residents have to choose an affiliation with a recognized 
mutual health insurance provider (“mutualiteit”). These providers reimburse (partially) all medical expenses 
recognized by the Government, and are funded by, on the one hand, employers’ and employees’ contributions 
• For all health end points covered by this study, we have asked two medical experts13 to identify 
medication14 that is typically used by chronic patients suffering from this affliction;   
• IMA has compared this list with drug prescriptions at the individual level to identify chronic 
patients for each illness15. 
• For each illness, the number of primary care consultations due to the illness is assumed to be 
equal to the difference between the average number of primary care consultations by identified 
patients, and the average number of primary care consultations by the general population.  
We illustrate this approach with our estimates of primary care consultations related to asthma.  
In the case of asthma, patients have been identified at the hand of their use of anti-inflammatory 
drugs. IMA has used drug prescriptions to provide the following estimate of the Flemish population 
of asthma patients: 
Table 17 : Flemish asthma population in 2006 
Age  
total 
population 
asthma 
population 
0-14  986 640 111 880 
15-64  3 988 880 140 160 
65+  1 085 240 102 .400 
In order to verify their validity, we have compared these estimates with the estimates from the 
Belgian Health Survey16: 
Table 18 Asthma prevalence Belgian Health Survey versus IMA 
 Belgian Health Survey (2004) IMA estimate 
Children (0-14) 4.4% 11% 
Men (15-54) 2.3% 3.5% 
Women (15-54) 2.6% 3.5% 
men (65+)  5.9% 9.4% 
                                                                                                                                                               
to social security and on the other hand, by the federal government. The IMA is an association that groups all 
the recognized mutual health insurance providers.  
13 Professor Nemery (Univeristy of Leuven) and Professor Desager (University of Antwerp).  
14 Characterised by the ATC Code, where ATC stands for Anatomical Therapeutic Chemical Classification 
System. The ATC is a classification system managed by the World Health Organisation, and classifies drugs, on 
the one hand according to the organs or systems they affect, and on the other hand according to their 
therapeutical and chemical properties.  
15 For obvious privacy reasons, these data have not been communicated to us.  
16 http://www.iph.fgov.be/EPIDEMIO/EPINL/crospnl/hisnl/his04nl/his22nl.pdf  
Women (65+) 5.3% 9.4% 
The IMA estimates are higher than the estimates of the Health Survey. These differences can be 
explained as follows:  
• The Health Survey is based upon direct questioning. It is possible that parents are reluctant to 
admit that their child is asthmatic.  
• The drugs for the treatment of asthma and Chronic Obstructive Pulmonary Disease (COPD) are 
often the same. In the age category 65+, a large proportion of patients using anti-inflammatory 
drugs are likely to suffer from COPD rather than from asthma.  
• A crucial parameter in the approach we have used is the threshold of annual drug use above 
which a patient can be considered to be chronic. If physicians are too eager to prescribe some 
types of drugs, this can lead to an overestimation of the number of chronic patients.  
As a next step, IMA has calculated the number of primary care consultations, both for the general 
population and for asthma patients. The difference between the two figures is entirely attributed to 
asthma. 
Table 19: Primary care consultations 
  
Primary care 
consultation of 
total population 
Primary care 
consultations of 
asthma patients 
Primary care 
consultations 
attributed to asthma 
0-14 jaar 2 .23 4 .2 1 .97 
15-64 jaar 3 .44 7 .63 4 .19 
65+ jaar 9 .27 14 .98 5 .71 
A similar procedure has been used: 
• to identify the people with upper respiratory problems,  
• to estimate the number of primary care consultations due to upper respiratory problems,  
• to estimate the number of days of bronchodilator use by asthma patients,  
• to identify people with allergic rhinitis and  
• to estimate the number of primary care consultations due to allergic rhinitis.  
We refer to the complete report for more details.  
Due to a lack of data, it has not been possible to apply this procedure to identify people with lower 
respiratory problems, to estimate the number of primary care consultations due to lower respiratory 
problems or to estimate the number of cough days. In these cases we have maintained the 
incidence or prevalence rates as reported in ExternE.  
Finally, there is a lack of reliable data on the number of new cases of chronic bronchitis. This health 
effect has therefore been dropped from the analysis.    
5.3 Treatment costs 
The RCM-MKG database is linked with a database containing the corresponding financial data, 
including the invoices. Thanks to this link, it is possible, in principle, to calculate the actual cost of 
any hospital admission. However, due to limitations imposed by privacy legislation, we have not 
been allowed to access these linked data to estimate the unit cost of emergency hospital 
admissions due to heart and respiratory problems. Instead, we have relied upon the cost estimates 
per Major Diagnostic Category (MDC) – this system classifies all major diagnoses in 25 mutually 
exclusive categories. An average treatment cost for each MDC is available from the Belgian 
Federal Health Ministry17. Clearly, such an “average” cost can only be a very gross approximation 
to the real cost.  
For the health effects that concern us, the average cost per hospital stay is18: 
Table 20. Average cost price of a hospital stay  
MDC Average cost in EUR (2008) 
Respiratory system 4,599.99 
Cardiovascular 5,246.77 
These figures have to be interpreted with great care, as there is no perfect correspondence 
between the MDC and the ICD used in ExternE. We are not aware of any information that could be 
used for a more detailed classification, or for an assessment of the margins of uncertainty. 
The unit costs of primary care consultations (21.53 EUR) have been obtained from IMA.  
In order to estimate the cost of bronchodilator use by asthma patients, we have assumed that 
Ventolin is representative. Its unit price is 4.99 EUR and it can be used for 25 daily doses.  
5.4 Productivity losses 
As noted above, there are three dimensions to productivity losses: 
• The loss of productivity on the regular labour market due to illness; 
• The lost household work due to illness and the informal care provided by relatives and friends; 
• The lost productivity due to premature death. 
In order to estimate the productivity losses on the regular labour market due to illness, we have 
used the periodic SDWorx survey on absenteeism. We have extrapolated the SDWorx sample to 
Flanders to obtain an estimate of the total cost of absenteeism in Flanders in 2007. The main 
limitations of our estimates are: 
• They only cover companies based in Flanders. These figures do not take into account the 
absenteeism of people who live in Flanders, but who work in Wallonia or in Brussels. 
Conversely, this table does include the absenteeism of people living in Wallonia or in Brussels, 
but who work in Flanders.  
• The SDWorx estimates only cover employees, not independent workers.  
 
Table 21 Absenteeism in Flanders based upon SDWorx study 
 Age Number of people Cost of illness Number of sick days Sick days per capita Cost per day of illness 
Men 15 -24  17.964 10.222.113 100.921 6 101 
                                                          
17 https://tct.fgov.be/etct/anonymous?lang=nl  
18 https://tct.fgov.be/etct/anonymous?lang=nl , Tabel 4.  
25 - 49  143.170 98.131.651 754.374 5 130 
50+ 35.193 25.171.687 172.464 5 146 
15 -24  14.553 6.689.648 78.953 5 85 
25 - 49  99.566 66.099.882 571.766 6 116 
Women 50+ 17.175 9.908.421 83.185 5 119 
Total  327.621 216.223.402 1.761.662 5 123 
 
It is noteworthy that the average number of sick days according to this estimate is somewhat lower 
than the estimate used in ExternE (7.2 days per person). 
In order to estimate the unit cost of lost household work, we have used the average value of “PWA 
cheques”19 (6.20 EUR per hour) as a lower bound. Due to a lack of reliable data with respect the 
unit cost of child care, we have not been able to assess the extra cost of paid child care due to 
illness. In order to assess the amounts of household work that is indeed lost, we have used the 
work by Glorieux et al. to estimate that an adult Flemish person spends 2.69 hours on household 
work per day.  
We have not considered the value of the informal work provided by relatives and family, for the 
following reasons: 
• It is very difficult to estimate the actual time invested in informal care, because this care takes 
place in parallel with normal household work. 
• It is not clear what unit cost should be attributed to this work if it does not come at the expense 
of work on the paid labour market. 
Finally, we have assumed that premature deaths due to pollution by PM and ozone do not lead to 
any productivity losses in Flanders. This is justified because, on average, the years of live lost 
occur after the legal retirement age.  Some studies have indicated that particulate pollution can lead 
to increased infant mortality, but there are legitimate reasons to doubt that these children would 
have reached the adult age anyway.  
5.5 WTP values 
On top of our estimates of the Cost-of-Illness, we have derived values relating to the non-market 
element of the willingness to pay i.e. WTP to avoid pain and suffering. 
To do so, we have explored the potential for reliably transferring values from appropriate existing 
studies, undertaken elsewhere, for use in the Flemish policy context.  
Value transfer increases the uncertainty in the estimated value since the time and/or place of the 
original study (the study site) will be different from the new decision making context. Thus, a crucial 
question becomes: What level of (in)accuracy is acceptable in cost-benefit analysis? Results from 
validity tests of value transfer procedures have shown that the uncertainty in spatial and temporal 
benefit transfer can be quite large.  
                                                          
19 PWA cheques are a payment instrument for services delivered by employees of PWAs (Plaatselijk 
Werkgelegenheidsagentschap of Local Employment Agency) – typically, these are people that have dropped 
out of the regular labour market, and who perform manual household tasks.  
There are two main approaches to benefit transfer: Unit Value Transfer with, and without, income 
adjustments; Function Transfer including Meta analysis. 
5.5.1 Unit value transfer 
Simple unit transfer is the easiest approach to transferring value estimates from one site to another. 
This approach assumes that the well-being experienced by an average individual at the study site is 
the same as will be experienced by the average individual at the policy site.  
The simple unit value transfer approach may not be appropriate where transfer between countries 
with different income levels and costs of living is intended. Instead, unit transfer with income 
adjustments may be applied. 
The adjusted benefit estimate Bp' at the policy site can be calculated as  
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where Bs is the original benefit estimate from the study site, Ys and Yp are the income levels at the 
study and policy site, respectively, and ß is the income elasticity of demand for the environmental 
good in question. There are, however, little empirical evidence on how the income elasticity of 
demand ß for different environmental goods and health impacts varies with income. 
However, it should be noted that even if adjustment for differences in income and cost of living in 
different countries are made, these will not account for differences in individual preferences, initial 
environmental quality, and cultural and institutional conditions between countries (or even within 
different parts of a country).  
5.5.2 Function transfer 
With the value (or benefit) function approach, an empirical relationship (function) between WTP and 
characteristics of the affected population and the resource being assessed is specified. For a stated 
preference study, the benefit function can be written as: 
 
eHbGbbWTP ijjij +++= 210  
where WTPij = the willingness-to-pay of household i at the study site j, Gj = the set of characteristics 
of the environmental good at site j, and Hij  = the set of characteristics of household i at site j, and 
b0 , b1  and  b2   are sets of parameters and e is the random error.  
To implement this approach the analyst has to find a study in the existing literature with estimates 
of the constant b0 and the sets of parameters, b1 and b2. Then the analyst has to collect data on the 
two groups of independent variables, G and H, at the policy site, insert them in the equation and 
calculate households´ willingness-to-pay at the policy site. 
The main problem with the benefit function approach arises from the possible exclusion of relevant 
variables in the WTP (or bid) function estimated in a single study.  
Transferring the entire value function is conceptually more appealing than just transferring unit 
values because more information is effectively taken into account in the transfer.  
5.5.3 Meta-analysis 
Instead of transferring the benefit function from one selected valuation study, results from several 
valuation studies could be combined in a meta-analysis to estimate one common benefit function. 
Meta-analysis has been used to synthesize research findings and improve the quality of literature 
reviews of valuation studies in order to come up with adjusted unit values. In a meta-analysis, 
several original studies are analysed as a group, where the result from each study is treated as a 
single observation in a regression analysis. If multiple results from each study are used, various 
meta-regression specifications can be used to account for such panel effects. The resulting 
regression equations explaining variations in unit values can then be used together with data 
collected on the independent variables in the model that describes the policy site to construct an 
adjusted unit value. The regression from a meta-analysis would look similar to the equation for 
function transfer, but with one added independent variable; Cs = characteristics of the study s (and 
the dependent variable would be WTPs = mean willingness-to-pay from study s). 
5.5.4 Premature mortality 
For premature mortality end-points, we have applied the survey data gathered in two recent stated 
preference research exercises20 to create value functions in which socio-economic data from 
Flanders is used to derive WTP values fitted to the Flemish context. This allowed us to explore a 
value transfer technique additional to relying on simple unit value transfer.  
In practice, however, analysis of the NEEDS data has found that the size of the errors associated 
with value function transfer are greater than those associated with unit value transfer. The statistical 
robustness of the results is found to be the greatest in the sample size afforded by pooling the data 
from nine countries covered by the original study. The recommendation is therefore to adopt the 
unadjusted 9-country pooled results from NEEDS as a low range estimate for the value of a life 
year (VOLY). 
The results from the single country analysis of the NewExt data seem to suffer from low sample 
sizes; none of the socio-economic variables one might expect to have a significant relationship with 
WTP were found to be significant. However, the 3-country pooled data analysis generated values of 
a statistical life (VSL) of the same order as previous analyses (e.g. CAFÉ CBA) and found income, 
amongst other socio-economic variables, to be significant. We have therefore adopted the results 
from the pooled value function transfer, using NewExt data, to provide a range for VSL and an 
upper bound VOLY estimate. The recommended values for mortality end-points are summarised in 
Table 22. 
 
Table 22. Recommended values for mortality end-points (€m, 2007 prices). 
 VSL VOLY Derived from: 
Lower value 0.83 0.027 NewExt; NEEDS 
Higher value 2.13 0.125 NewExt 
 
5.5.5 Morbidity 
Previous analysis on the most comprehensive and recent data collected on the valuation of 
morbidity end-points (Ready et. al. 2004), had concluded that unit value transfer was likely to be as 
accurate as function value transfer. We therefore adopted a unit value transfer process for the pain 
and suffering component of WTP, applying to the results of the pooled sample from the five country 
                                                          
20 The EC funded projects NEWEXT (Markandya et al. (2004)) and NEEDS (Rabl et al. (2006)). The NewExt 
results for mortality valuation have been used in the CAFE cost-benefit analysis.  
study reported in Ready et. al. The recommended morbidity “pain and suffering” values are 
therefore those presented in Table 23.  
Table 23. Transferred Flemish Pain & Suffering WTP components - Morbidity 
Health endpoint Central unit values (€2007) 
Hospital admission 549 
ERV for respiratory illness 284 
GP visit – asthma 18 
GP visit - lower respiratory symptoms 45 
Respiratory symptoms in asthmatic adult 163 
Respiratory symptoms in asthmatic child 346 
Respiratory medication use 1 
Restricted activity day (working adult) 58 
Restricted activity day (age > 65) 58 
Restricted activity day (needs to stay in bed) 58 
Restricted activity day (work loss day) 48 
Minor restricted activity day 48 
Cough day 48 
Symptom day 48 
Work loss day 48 
Minor restricted activity day 48 
Chronic bronchitis 234,731 
 
6 Estimate of environmental health costs in Flanders 
We have used the data described in Section 5 to estimate total environment related health costs 
corresponding to changes in the existing ambient concentrations of ozone and PM. The effects 
have always been calculated for changes of 10 µg/m3 for each pollutant and per year. 
We have considered the following effects:  
• Premature mortality  
• Morbidity linked to PM10 
• Morbidity linked to PM2,5 
• Morbidity linked to ozone 
The approach always consists in the following steps: 
• We start with CRF used in the CAFE and ExternE projects;  
• If there are Flemish data on the background rates, we combine them with the CRF to obtain an 
impact function;  
• If there are no Flemish data on the background rates, we use the impact function estimated in 
ExternE; 
• We combine the impact function with the unit cost (COI or WTP) to calculate the annual cost 
linked to an increase of ambient concentration levels of the pollutant with 10 µg/m3 . 
The costs we consider here are thus marginal costs: they are the costs linked to small changes in 
the existing concentrations of the pollutants under consideration. Using this method to calculate the 
total cost of air pollution in Flanders (rather than the marginal cost) is only valid if the estimate of 
the CRF is also reliable in the (purely hypothetical and unknown) reference point without pollution 
induced by human activity. We are not aware of any studies indicating that such an extrapolation 
would be acceptable.  
To put the figures below in perspective, note that according to the most recent report of the Flemish 
Environmental Agency21, the average annual concentrations of PM lay in the following intervals:  
• PM10: between 21 µg/m³ and 38 µg/m³.  
• PM2.5: between 17 and 23 µg/m³ 
For ozone, the 2004 average concentration was 68.5 µg/m³. In 2008, the 8 hours average 
concentration did not exceed 120 µg/m3 for more than 28 days.  
If possible, we do not only report the central value of each estimate, but also the lower bound (LB) 
and the upper bound (UB) of the estimated 95% confidence intervals. Wherever we calculate the 
sum of the effects, we shall assume that these are stochastically independent, and thus that the 
lower bound (upper bound) of the combined effects can be calculated as the sum of the lower 
bounds (upper bounds) of the individual effects. Note that this assumption is only introduced 
because of a lack of data – the estimates need thus to be interpreted with a lot of circumspection.  
                                                          
21 VLAAMSE MILIEUMAATSCHAPPIJ (2009), Luchtkwaliteit in het Vlaamse Gewest. Jaarverslag 
Immissiemeetnetten. Kalenderjaar 2008.  
6.1 Mortality effects 
In 2005 (most recent data when the study was written22) 56 890 people died in Flanders. We will 
use this as the background rate for the impact function.  
The CRF used in CAFÉ has shown that a one-off decrease of ambient  PM2,5 concentration with 
10 µg/m3 during one year leads to a gain of 651 expected life years per 100 000 people over a 
period of 10 year. As Flanders currently has 6 078 600 inhabitants23, this corresponds to 39 572 life 
years for Flanders taken in its totality. 
Using the VOLY values reported in Table 22, we obtain the following estimate of the cost of chronic 
mortality due to 10 µg/m3 PM2.5:  
Table 24 Cost of chronic mortality due to 10 µg/m3 PM2,5 (VOLY measure). 
LB VOLY UB VOLY 
1,126 million EUR 5,762 million EUR 
If we combine the CRF used in CAFE with Flemish mortality figures, we obtain that an increase of 
PM10 concentrations with 10 µg/m3 per year leads to 341 additional premature deaths. Using the 
VOLY values reported in Table 22, we obtain the following estimate of the cost of acute mortality 
due to 10 µg/m3 PM10: 
Table 25 Cost of acute mortality due to 10 µg/m3 PM10 (VSL measure). 
LB VSL UB VSL 
330 million EUR 847 million EUR 
If we combine the CRF used in CAFE with Flemish mortality figures, we obtain that an increase of 
ozone concentrations with 10 µg/m3 per year leads to 171 additional premature deaths.  Using the 
VOLY values reported in Table 22, we obtain the following estimate of the cost of acute mortality 
due to 10 µg/m3 ozone: 
Table 26 Cost of acute mortality due to 10 µg/m3 ozone (VSL measure). 
 Central value of CRF LB CRF UB CRF 
Number of premature deaths 170,67 56,89 244,627 
Lower estimate VSL 165 000 026 55 000 009 236 500 037 
Higher estimate VSL 423 433 801 141 144 600 606 921 782 
We see here that the combination of two sources of uncertainty (the uncertainty with respect to the 
slop of the CRF on the one hand and the uncertainty regarding the unit values of the VSL on the 
other hand) lead to a very large difference (factor 10) between the lower bound (55 million EUR) 
and the lower bound (607 million EUR) of the estimate.   
                                                          
22 http://www.statbel.fgov.be/downloads/deaths_nl.xls   
23 http://www.statbel.fgov.be/verkiezingen2006/downloads/com_gem_02000_nl.pdf  
Mortality data for babies have been obtained from the Flemish Health Agency24: 
Table 27: Postneonatal mortality in Flanders 
year Number of births 
Postneonatal deaths 
 per 1000 births  
Total postneonatal  
deaths 
2006 66.139 1.5 99.2085 
 
If we combine the CRF used in CAFE with Flemish mortality figures, we obtain the following impact 
function: 
Table 28: Impact function for acute infant mortality due to PM10 
 Central value  OG BG 
Effect on number of deaths 3.96834 1.98417 6.944595 
In order to calculate the VSL of an infant we use the MRS for an adult VSL as recommended in 
CAFÉ (see Section 3). This implies that we take a lower value of 874 820 EUR and a higher value 
of 4 490 040 EUR. 
Table 29 Cost of acute infant mortality due to 10 µg/m3 PM10 (VSL approach) 
 Central value  LB HB 
Lower value VSL 3 836 504 1 918 252 6 713 883 
Higher value VSL 19 690 974 9 845 487 34 459 205 
Again, we see that the combination of two sources of uncertainty leads to a factor 10 difference 
between the higher and the lower estimate. Notwithstanding these high margins of uncertainty, we 
see that the cost of infant mortality is relatively low compared to the costs of premature adult 
mortality. This is uniquely due to the very low background share of post neonatal mortality in total 
mortality – both the VSL and the slope of the CRF are much higher than the corresponding figures 
for adults.  
6.2 Morbidity linked to PM10 
We have combined the CRFs used in CAFE with our estimates of the COI and with the WTP 
estimates summarized in Table 23  to obtain the following summary of PM10 related health costs in 
Flanders:  
Table 30: Morbidity effects attributed to 10mg/m³ PM 10  
Effect Average Lower 
bound 
Upper 
bound 
COI       
Emergency hospital admission due to respiratory problems 2 844 239 1 546 867 4 166 560 
Emergency hospital admission due to heart problems 1 412 223 706 112 2 118 335 
                                                          
24 http://www.zorg-en-gezondheid.be/topPage.aspx?id=4828  
Primary physician consultation due to asthma 255 997 76 071 440 680 
Primary physician consultation due to upper respiratory problems (with the 
exception of allergic rhinitis) 
126 017 64 252 192 711 
Bronchodilator use 39 034 -42 876 123 639 
Total COI 4 677 510 2 350 425 7 041 925 
WTP       
Emergency hospital admission due to respiratory problems 
185 084 100 660 271 132 
Emergency hospital admission due to heart problems 
155 749 77 874 233 623 
Primary physician consultation due to asthma 225 581 67 033 388 322 
Lower respiratory problems (adults) 
94 475 712 11 164 776 177 043 980 
Lower respiratory problems (children) 
70 743 482 35 477 539 105 799 717 
Total WTP 165 785 608 46 887 882 283 736 774 
Total COI + WTP 170 463 118 49 238 308 290 778 699 
 
There are two noteworthy observations to make.  
First, the willingness to pay to avoid the pain and suffering linked to lower respiratory problems is 
obviously the most important cost category – it corresponds to 97% of the total cost!  
Second, the uncertainty surroundings these estimates is very important, as there is a factor 5 
difference between the upper and the lower bound of the confidence intervals. Moreover, these 
margins are based uniquely on the confidence intervals of the CRF, and do not take into account 
the numerous other uncertainties.   
 
6.3 Morbidity linked to PM2.5 
We have combined the CRFs used in CAFE with our estimates of the COI and with the WTP 
estimates summarized in Table 23  to obtain the following summary of PM2.5 related health costs 
in Flanders:  
Table 31: Morbidity effects attributed to 10mg/m³ PM2.5 
Effect Average Lower bound Upper bound 
Productivity loss due to 
absenteeism  
77 660 174 65 842 321 89 478 027 
Cost of lost Household work 60 217 281 52 864 434 67 570 128 
WTP to avoid days with 
restricted activity  221 545 670 194 493 777 248 597 562 
Total  359 423 125 313 200 533 405 645 717 
The cost of morbidity attributed to PM2.5 is thus higher than the cost of morbidity attributed to the 
same concentration of PM10. In this case as well, the “subjective” health costs are higher than the 
“real” economic costs due to productivity losses. Finally, the margins of uncertainty are much lower 
in the case of PM2.5 than in the case of PM10.  
 
6.4 Morbidity linked to ozone 
We have combined the CRFs used in CAFE with our estimates of the COI and with the WTP 
estimates summarized in Table 23  to obtain the following summary of ozone related health costs in 
Flanders:  
Table 32: Morbidity effects attributed to 10mg/m³ ozone 
Effect Average LB UB 
COI       
Hospital admissions due to 
respiratory problems 
amongst 65+ 
781 641 -312  656 1 875 938 
Lost household work 7 731 215 2 977 562 12 432 629 
Primary physician 
consultations due to 
allergic rhinitis 
914 171 691 959 1 169 635 
Bronchodilator use by 
children  
60 765 8 457 113 228 
Bronchodilator use by 
adults 
34 508 -11 547 76 417 
Total COI 9 522 300 3 353 774 15 667 847 
WTP       
Hospital admissions due to 
respiratory problems 
amongst 65+ 50 864 -20 346 122 073 
Minor restricted activity 
days (adults) 23 452 309 9 032 308 37 713 849 
Coughing by children 35 546 605 -7 132 368 84 991 448 
Other lower respiratory 
problems (children) 
6 182 549 -16 514 034 30 857 229 
Total WTP 65 232 327 -14 634 439 153 684 600 
Total COI + WTP 74 754 627 -11 280 665 169 352 447 
It is clear that the most important cost categories are the willingness to pay to avoid the coughing 
by children and to reduce the minor restricted activity days for adults. However, there is a large 
uncertainty surrounding the estimate for the willingness to pay to reduce coughing by children – it is 
not even significantly different from zero!  
It is also noteworthy that even the lower estimate of the costs of the mortality effects of ozone is 
twice as high as the central value of the costs of the morbidity effects.  
 
7 Conclusion and policy recommendations 
The estimates provided in this study are subject to numerous sources of uncertainty:  
• A lot of questions surround the validity of the unit costs used in the study (both the “real” costs 
of illness as the “subjective” willingness’s to pay). 
• With the current state of knowledge, it would make little sense to work on more detailed 
inventories of ambient concentrations or on more refined exposure scenarios. Indeed, the CRFs 
that are currently used are not differentiated across time and space anyway. Moreover, a lot of 
uncertainty surrounds the relative magnitude of the variance of exposure across the Flemish 
territory compared to the variance per grid of 4x4 km. Therefore, only average concentrations 
can be taken into account. 
• The margins of uncertainty surrounding the estimates of the CRFs have been calculated with 
statistical techniques and are explicit. It is however unknown to what extent the estimated 
effects are correlated. 
• Our estimates of the cost of illness are not based upon actual expenditures. To estimate the 
cost of hospital admissions, we had to use “standard costs”. Our estimates of the prevalence of 
some chronic afflictions and of primary care consultations are also based upon indirect methods 
(estimates of the use of prescription drugs).  
• In our estimates of the productivity losses, we have not been able to estimate the cost of 
additional child care or of informal care provided by relatives and friends.  We have not taken 
into account absenteeism of people who reside in Flanders but work in Brussels.  
• Value transfer is a helpful tool for generating WTP estimates in case no or few resources are 
available for developing original stated preference studies in the study site. However, the 
transfer error can be significant. In practice, we do not know what the size of the real error 
introduced by using value transfer is. There is a strong case for employing further sensitivity of 
e.g. 20% around the values we have recommended to account for value transfer error. There is 
clearly also an extremely good case for undertaking primary research in Flanders.     
• On the one hand, the estimated health effects do not give an exhaustive view of all possible 
health impacts of air pollution. On the other hand, there is also some overlap in the effects that 
we have described.  
Despite the large uncertainty surrounding individual estimates, we can be confident about the order 
of magnitude of the yearly marginal “cost of illness” due to PM2.5, PM10 and ozone (a few dozens 
of millions EUR per 10µg/m³). If we also take into account the “subjective” health costs, our 
estimates run in the billion EUR.  
The most important health effects identified in this study are:  
• Premature deaths due to chronic exposure to PM2.5 
• Premature deaths due to acute exposure to PM10 
• Premature deaths due to acute exposure to ozone 
• The pain and suffering following from lower respiratory problems attributed to PM10 
• The pain and suffering following from restricted activity attributed to acute exposure to PM2.5 
• The productivity losses and the lost household work due to acute exposure to PM2.5 
• The pain and suffering due to minor restricted activity days (amongst adults) and to cough days 
(amongst children), attributed to acute exposure to ozone.  
The essential problem is that all our calculations are based upon epidemiological studies and 
administrative databases that have not been organised with the research questions of this study in 
mind. In an ideal world, a study of environment related health costs would start with an inventory of 
the health endpoints that need to be studied. Based upon this inventory, one would draft an 
exhaustive and non-overlapping list of studies that need to be performed in Flanders. Due to budget 
restrictions, this is probably not possible, and one will have to do with the results of “ad hoc” studies 
that have been undertaken in a different context and with other objectives in mind.  
However, this does not need to come at a large cost: our research has shown that relatively small 
changes in existing structural surveys (such as the Belgian Health Surveys) and in the organisation 
of administrative databases could lead to significant improvements compared to the current 
situation – we refer to the complete report for more details on this issue. 
With respect to the valuation of the “subjective” health impacts, we identified three options that 
Flemish authorities may consider. The options include: 
• rely on existing estimates, transferred from other countries; 
• replicate the most recent stated preference exercises in Flanders; 
• develop a bespoke valuation method to fit the Flemish context.  
In the complete report, we have evaluated these options, drawing out the relative merits and 
limitations of each. The key trade-off is between cost (option (a) being free whilst option (c) costing 
circa €250,000) and level of certainty in the values. At present, transferred values from other 
studies can be used. However, they bring with them a high degree of uncertainty, resulting from the 
methods used to derive the original values and the transfer process itself. 
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